Fig. 2

Investigators’ global disease status/progression ratings for patients at their own study site. Patients in the early-IT group received idursulfase-IT in the phase 2/3 and extension studies; patients in the delayed-IT group initiated treatment with idursulfase-IT in the extension study. ^aIncludes nine patients aged under 3 years enrolled in the substudy as part of the early-IT population. ^bExcludes nine patients aged under 3 years enrolled in the substudy. IT, intrathecal